ATLANTA, GA--(MARKET WIRE)--Jan 7, 2008 -- MIV Therapeutics, Inc. (OTC BB:MIVT.OB - News) (Frankfurt:MIV.F - News), a leading developer of next-generation coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, today announced that Dr. Mark Landy, president, will assume the additional position of chief executive officer of the company effective today. He assumes this position from Alan Lindsay, who will remain chairman of the board of MIV Therapeutics.

ADVERTISEMENT

Dr. Landy joined MIV as president in April 2006. Prior to his employment at MIV, he was, from 2004, a Senior Research Analyst with Susquehanna Financial Group in Atlanta, establishing the company's Medical Supplies and Device Research group and was ranked as the Firm's top healthcare analyst by institutional clients in 2005 and 2004. From 2001 to 2004, Dr. Landy was a Director and Senior Research Analyst (Medical Devices) with Leerink Swann & Company in Boston.

"This promotion is well-deserved recognition for the excellent progress Mark has made in advancing the commercialization of our technology, with the most recent achievement being strong data from our First-in-Man study of our drug eluting stent," commented Alan Lindsay. "He has brought new focus to the company, adding our own stent manufacturing, expanding our product pipeline and forging collaborations with world-class companies, while judiciously controlling costs and streamlining operations," Mr. Lindsay added. "In addition, Dr. Landy was instrumental in bringing new financing to MIV and broadening our shareholder base to include several highly-regarded institutional investors."

Dr. Landy obtained a Bachelor of Business Administration from the University of Pennsylvania Wharton School of Business in 1996, and a Doctor of Dental Surgery from the University of Witwatersrand in Johannesburg, South Africa, in 1991. He has also served as a director of MIV since June 1, 2006.

About MIV Therapeutics

MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents, as well as for a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. This coating platform is derived from hydroxyapatite (HAp), an organic material that has demonstrated excellent in vivo safety and biocompatibility. Hydroxyapatite is a porous material that makes up the bone mineral and matrix of teeth, and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug-eluting technologies based on HAp could also provide an attractive alternative to current polymer-based drug-eluting coatings on the stent market, which have been associated with undesirable effects. The Company's drug-eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIV Therapeutics has a Collaborative Research Agreement with the University of British Columbia and has received a government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents," under the National Research Council-Industrial Research Assistance Program. Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization. MIV's intellectual property portfolio includes patents held by the University of British Columbia and exclusively licensed to MIV. Key patent applications filed simultaneously in various countries around the world further protect the commercial exclusivity of MIV's inventions in the global marketplace. For more information, please visit www.mivtherapeutics.com.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "proposed," "expected," "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties including, without limitation, the closing of the Share Purchase Agreement, the ability of the Company to raise sufficient funding and to continue to develop its various business interests as presently contemplated. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

     CONTACTS:
     MIV Therapeutics Inc.
     Anthony L. Huston
     Director of Investor Relations
     (604) 301-9545, x14
     (800) 221-5108
     ahuston@mivtherapeutics.com
     investor@mivtherapeutics.com
      
     Lippert/Heilshorn & Associates, Inc.
     Kim Sutton Golodetz
     kgolodetz@lhai.com
     Emmanuelle Ferrer
     eferrer@lhai.com
     (212) 838-3777